Research Pharmacists Have Unique Responsibilities
June 8th 2021Working in clinical research combines skills from both the retail and health system pharmacy spaces, as well as other, more unique skillsets, according to research pharmacist Brian Wortz, PharmD, of Cancer Treatment Centers of America, in an interview with Pharmacy Times.
Pharmacy Students Were Crucial to COVID-19 Testing, Vaccination Efforts
June 8th 2021Several third-year pharmacy students at the Washington State University College of Pharmacy and Pharmaceutical Sciences said they were involved with COVID-19 testing and vaccination efforts, including organizing mass vaccination events and testing patients in their communities.
Assessing Future Treatment Options for Patients With Resectable Non-Small Cell Lung Cancer
June 7th 2021Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what the findings of the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer may mean for future treatment options.
Advanced Prostate Cancer Treatment Landscape May Shift Due to New Investigative Treatment
June 6th 2021If it were to be approved now, the drug would be used in patients with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor-directed therapy and 1 to 2 taxane-based chemotherapeutics.
Assessing the Adverse Events From Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors
June 5th 2021Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses some of the adverse events patients experienced during the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
The Efficacy, Safety of Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors
June 4th 2021Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the efficacy and safety of lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
An Overview of the Phase 3 Trial Assessing Lutetium Lu 177 Dotatate for Midgut Neuroendocrine Tumors
June 4th 2021Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, gives an overview of the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.